Spots Global Cancer Trial Database for Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer

Official Title: Organ Preservation With Active Surveillance After Chemoradiation in Rectal Cancer (OPTION)

Study ID: NCT03594630

Conditions

Rectal Adenocarcinoma

Stage II Rectal Cancer AJCC v8

Stage IIA Rectal Cancer AJCC v8

Stage IIB Rectal Cancer AJCC v8

Stage IIC Rectal Cancer AJCC v8

Stage III Rectal Cancer AJCC v8

Stage IIIA Rectal Cancer AJCC v8

Stage IIIB Rectal Cancer AJCC v8

Stage IIIC Rectal Cancer AJCC v8

Interventions

Chemotherapy

Patient Observation

Questionnaire Administration

Resection of Rectum

Study Description

Brief Summary: This pilot trial studies how well active surveillance and chemotherapy before surgery work in treating participants with stage II-III rectal cancer. Active surveillance involves monitoring participants for additional tumor growth after receiving cancer treatment. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether deferring surgery after active surveillance and chemotherapy will work better in treating participants with stage II-III rectal cancer.

Detailed Description: PRIMARY OBJECTIVES: I. To quantify the rates of organ preservation and tumor regrowth with non-operative management of locally advanced rectal cancer in patients achieving a clinical complete response (cCR). SECONDARY OBJECTIVES: I. To correlate clinical, radiographic, and pathologic findings after neoadjuvant therapy for rectal cancer. II. To determine the impact of active surveillance with deferral of surgery on oncologic outcomes. III. To assess decision quality for patients with rectal cancer facing multiple treatment options. IV. To explore the impact of patient-provider communication on patient decisions for surgical versus nonsurgical treatment decision for rectal cancer. V. To assess safety of deferral of surgery in distal rectal cancer patients with possibility of cohort expansion to more proximal locally advanced rectal cancer patients. CORRELATIVE OBJECTIVES: I. Obtain tissue to monitor treatment response and any future biomarker analyses OUTLINE: Participants are assigned to 1 of 2 groups. GROUP I: Participants who have achieved clinical complete response undergo standard surgical resection. GROUP II: Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I. After the completion of study treatment, participants in Group I are followed up at 6 and 12 months, and then once a year for up to 3 years. Participants in Group II are followed up every 3 months for 18 months, every 6 months for 2 years, and then every year for up to 3 years.